MCD 386

Drug Profile

MCD 386

Alternative Names: CDD-0102; CDD-0102-J; MCD-386; MCD-386 Forte; MCD-386 Forte/Transderm; MCD-386 Transderm; MCD-386CR

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Toledo
  • Developer Mithridion
  • Class Antidementias; Oxadiazoles; Pyrimidines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Progressive supranuclear palsy; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Progressive-supranuclear-palsy in USA (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top